Skye Bioscience (SKYE) News Today $3.50 +0.02 (+0.57%) Closing price 04:00 PM EasternExtended Trading$3.50 0.00 (0.00%) As of 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SKYE Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Skye Bioscience to host KOL event on CBeyond Phase 2a clinical data readoutAugust 27 at 10:05 PM | msn.comSkye Bioscience to Host Virtual KOL Event and Provide Perspectives on Upcoming CBeyond™ Phase 2a Topline Clinical Data ReadoutAugust 27 at 7:00 AM | globenewswire.comSkye Bioscience, Inc. (NASDAQ:SKYE) Receives $15.50 Average PT from AnalystsAugust 25, 2025 | americanbankingnews.comSkye Bioscience, Inc. (NASDAQ:SKYE) Given Consensus Recommendation of "Buy" by AnalystsAugust 24, 2025 | marketbeat.comSkye Bioscience (NASDAQ:SKYE) Major Shareholder 5Am Partners Vii, Llc Sells 60,956 SharesAugust 23, 2025 | insidertrades.comSkye Bioscience, Inc. to Present at Multiple Investment and Medical Conferences in September 2025August 21, 2025 | quiverquant.comQSkye Bioscience to Participate in Upcoming Investment and Medical ConferencesAugust 21, 2025 | globenewswire.comSkye Bioscience (NASDAQ:SKYE) Upgraded by Evercore ISI to Strong-Buy RatingAugust 18, 2025 | marketbeat.comEvercore ISI Group Initiates Coverage of Skye Bioscience (SKYE) with Outperform RecommendationAugust 16, 2025 | msn.comEvercore starts Skye Bioscience at Outperform on nimacimab potentialAugust 14, 2025 | msn.comSkye Bioscience initiated with an Outperform at Evercore ISIAugust 14, 2025 | msn.comSkye Bioscience, Inc. (NASDAQ:SKYE) is Altium Capital Management LLC's 9th Largest PositionAugust 14, 2025 | marketbeat.comSkye Bioscience Earnings Call: Positive Outlook Amid ChallengesAugust 13, 2025 | msn.comSkye Bioscience Inc (SKYE) Q2 2025 Earnings Call Highlights: Promising Trial Progress Amid ...August 9, 2025 | finance.yahoo.comSkye Bioscience signals late Q3/early Q4 top-line Phase IIa results as nimacimab advances obesity treatment platformAugust 9, 2025 | msn.comSkye Bioscience, Inc. (SKYE) Q2 2025 Earnings Call TranscriptAugust 7, 2025 | seekingalpha.comSkye Bioscience Reports Second Quarter 2025 Financial Results and Business UpdateAugust 7, 2025 | globenewswire.comWe Think Skye Bioscience (NASDAQ:SKYE) Needs To Drive Business Growth CarefullyAugust 6, 2025 | finance.yahoo.comSkye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025July 30, 2025 | globenewswire.comSkye Bioscience, Inc. (NASDAQ:SKYE) Given Average Recommendation of "Buy" by AnalystsJuly 28, 2025 | marketbeat.comSkye Bioscience (NASDAQ:SKYE) Shares Down 8% - What's Next?July 25, 2025 | marketbeat.comSKYE Stock Price Quote | MorningstarJuly 11, 2025 | morningstar.comMSkye Bioscience, Inc. (SKYE) - Yahoo FinanceJuly 9, 2025 | finance.yahoo.comSkye Bioscience Highlights Nimacimab’s Promise in Obesity Treatment, Anticipates Phase 2a DataJuly 6, 2025 | msn.comSkye Bioscience, Inc. (NASDAQ:SKYE) Given Consensus Rating of "Buy" by BrokeragesJuly 3, 2025 | marketbeat.comPositive week for Skye Bioscience, Inc. (NASDAQ:SKYE) institutional investors who lost 53% over the past yearJune 25, 2025 | finance.yahoo.comSkye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes ... - MorningstarJune 24, 2025 | morningstar.comMSkye Bioscience Launches "Anatomy of Progress" Video Series on Nimacimab Development for Obesity Treatment - NasdaqJune 24, 2025 | nasdaq.comSkye Bioscience (NASDAQ:SKYE) Receives "Market Outperform" Rating from JMP SecuritiesJune 24, 2025 | marketbeat.comSkye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association's 85th Scientific SessionsJune 23, 2025 | globenewswire.comSkye Bioscience (NASDAQ:SKYE) Trading 23.1% Higher - Should You Buy?June 20, 2025 | marketbeat.comSkye confirms phase 2 data on nimacimab for obesity expected later this yearJune 19, 2025 | msn.comSkye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association’s 85th Scientific SessionsJune 17, 2025 | finance.yahoo.comSkye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association's 85th Scientific SessionsJune 17, 2025 | globenewswire.comCantor Fitzgerald Weighs in on Skye Bioscience FY2026 EarningsJune 12, 2025 | marketbeat.comCantor Fitzgerald Predicts Skye Bioscience FY2026 EarningsJune 10, 2025 | marketbeat.comSkye Bioscience, Inc. (NASDAQ:SKYE) Receives Average Rating of "Buy" from AnalystsJune 8, 2025 | marketbeat.comSkye Bioscience, Inc. (NASDAQ:SKYE) Given Average Recommendation of "Buy" by BrokeragesJune 8, 2025 | marketbeat.comSkye Bioscience (NASDAQ:SKYE) Trading Up 24% - Here's What HappenedMay 31, 2025 | marketbeat.comSkye Bioscience to Participate in Upcoming Investment ConferencesMay 22, 2025 | globenewswire.comSkye And Arecor Partner To Develop Advanced Nimacimab Formulation For Obesity TreatmentMay 21, 2025 | nasdaq.comArecor shares climb 18% on collaboration with Skye BioscienceMay 19, 2025 | lse.co.ukSkye Bioscience, Inc.: Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate NimacimabMay 19, 2025 | finanznachrichten.deSkye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate NimacimabMay 19, 2025 | globenewswire.comEnsign Peak Advisors Inc Sells 132,713 Shares of Skye Bioscience, Inc. (NASDAQ:SKYE)May 18, 2025 | marketbeat.comSkye Bioscience, Inc. (NASDAQ:SKYE) Receives Consensus Rating of "Buy" from AnalystsMay 16, 2025 | marketbeat.comSkye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 13, 2025 | globenewswire.comSkye Bioscience Clinical Model Demonstrating Necessity of Peripheral CB1 Inhibition for Weight Loss Presented at European Congress on ObesityMay 13, 2025 | globenewswire.comSkye Bioscience (NASDAQ:SKYE) Issues Quarterly Earnings ResultsMay 12, 2025 | marketbeat.comEarnings call transcript: Skye Bioscience Reports Q1 2025 Financials Amid R&D ExpansionMay 10, 2025 | investing.com Get Skye Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for SKYE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SKYE Media Mentions By Week SKYE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SKYE News Sentiment▼-0.081.03▲Average Medical News Sentiment SKYE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SKYE Articles This Week▼103▲SKYE Articles Average Week Get the Latest News and Ratings for SKYE and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Skye Bioscience and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies REPL News ESPR News RGNX News AURA News CMPS News CRVS News YMAB News AQST News VIGL News CMPX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SKYE) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Skye Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Skye Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access